Retatrutide in Canada

Retatrutide in Canada sits in an unusual place: it is one of the most searched research peptides in the country, yet it is not an authorised drug here, it has no Drug Identification Number, and no Canadian marketing submission for it is publicly listed. This page answers the questions Canadians actually ask about retatrutide, in plain language: what the molecule is, where it stands with Health Canada, what “research-grade” means in law and in the lab, and how research groups in Canada verify what they receive.

It is written for researchers, lab managers and purchasing staff. It is an information page, not a product listing, and nothing on it describes or supports use in people or animals.

Retatrutide Canada: the short answer

What retatrutide is

Retatrutide is the non-proprietary name for LY3437943, an investigational peptide discovered by Eli Lilly and Company. It is a single engineered peptide chain designed to act at three related receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 receptor and the glucagon receptor. Because it engages all three, the literature describes it as a triple agonist, and it is often shortened online to “reta”.

Chemically it is a 39-residue peptide built on a GIP-derived backbone. Three of its residues are not among the twenty amino acids coded by genes, and a long-chain fatty diacid is attached through a linker to one lysine side chain. That lipid lets the molecule bind serum albumin, which is the design feature behind its long persistence in laboratory and preclinical systems. Its molecular formula is C₂₂₁H₃₄₂N₄₆O₆₈ and its average molecular mass is roughly 4,731 g/mol.

For the receptor pharmacology, the non-coded residues and the analytical chemistry in depth, see our research article Retatrutide (LY3437943): structure, receptor pharmacology and analysis.

Where retatrutide stands with Health Canada

In Canada, a pharmaceutical for human use generally cannot be sold until Health Canada has reviewed a submission and issued a Notice of Compliance, and the product has been assigned a Drug Identification Number. Retatrutide has neither. It also does not appear on Health Canada’s published list of new drug submissions currently under review, which covers pending applications by medicinal ingredient. In practical terms that means Canadian authorisation is not a near-term event: a review cannot finish before a submission has even been filed.

Outside Canada the picture is similar. No regulator in any country has authorised retatrutide. Public reporting in July and August 2026 described the developer’s plan to seek United States approval in the first quarter of 2027, later than it had first expected. There is also an unusual regulatory argument running in the United States about whether a peptide of this size should be classed as a biologic or as a conventional drug. That argument turns on how many alpha amino acids the molecule contains, and it matters there because the two pathways carry different periods of market exclusivity. It has no bearing on the Canadian position, which is simply that the molecule is unauthorised for human use.

Why it is called “GLP-3” online

A large share of Canadian searches for retatrutide use the nickname “GLP-3”. That label is informal: there is no hormone called GLP-3 and no receptor by that name. The nickname appeared because retatrutide acts at three receptors, and people extended the familiar shorthand for single-receptor compounds by one. Scientific papers do not use the term, and it should not be taken as a chemical or regulatory name.

What research-grade retatrutide should come with

Retatrutide is one of the harder research peptides to make and to verify. It is long, it carries a lipid, and it contains residues that standard sequencing libraries do not expect. That makes documentation more important than for a short peptide. Before a Canadian lab accepts research-grade material, it is reasonable to expect the following:

1. An HPLC purity result with the chromatogram, not just a percentage, so the main peak and any shoulders can be seen.
2. A mass spectrometry identity result confirming the intact molecule at about 4,731 g/mol. For this molecule the intact mass is the more important check, because a lipidated impurity can elute close to the main peak and flatter an HPLC figure.
3. Independent testing. A report from a third-party laboratory carries more weight than an in-house figure.
4. A clear link between the certificate and the vial. ExoLabz vials are matched to their published certificate by cap and crimp colour rather than by a printed batch number, and certificates are published for some products on our COA page.
5. A realistic content statement. A vial label gives the nominal mass of powder, which includes counter-ion and residual water, so the net peptide content is lower than the label figure. See net peptide content explained.

How to read those documents is covered in how to read a peptide certificate of analysis and why purity figures on two certificates can disagree.

Shipping and storing retatrutide in Canada

Retatrutide research material is supplied as a lyophilised powder. In that dry form a peptide is far more tolerant of temperature than it is in solution, but it still benefits from short, predictable transit. A domestic Canadian shipment avoids customs holds, import duty and brokerage fees, and it avoids the days a parcel can spend in a clearance queue at an unknown temperature.

Canada adds its own seasonal problems. In winter a parcel can sit in an unheated depot or on a porch well below freezing, and in summer a delivery vehicle in the Prairies or southern Ontario can run hot. Neither is ideal, though brief cold is generally kinder to a dry powder than sustained heat. On arrival, move vials to refrigerated storage at 2–8 °C, keep them in their cartons away from light, and log the receipt date alongside the cap and crimp colours. Our guides to storage and stability of lyophilised peptides and checks to run when a shipment arrives cover the detail.

Retatrutide in Canada: frequently asked questions

Is retatrutide available in Canada?

Not as a medicine. There is no authorised retatrutide product in Canada and none can be prescribed. Research-grade material is available to laboratories from Canadian research suppliers for in-vitro and analytical work only.

Can a doctor prescribe retatrutide in Canada?

No. A prescription requires an authorised drug product, and retatrutide has no Canadian market authorisation or DIN.

When will retatrutide be approved in Canada?

Nobody can give a date. No Canadian submission is publicly listed, the developer’s first planned filing is in the United States in early 2027, and a Canadian review can only begin once a submission is made. Anyone quoting a firm Canadian approval date is guessing.

What does retatrutide cost in Canada?

There is no pharmacy or retail price, because there is no authorised product. Research-grade material is priced by suppliers per vial, and the fair way to compare offers is cost per milligram of actual peptide, adjusted for net peptide content and purity. See comparing research peptide prices per milligram.

Is retatrutide the same as semaglutide or tirzepatide?

No. They are three different molecules. Semaglutide is designed around a single receptor, tirzepatide around two, and retatrutide around three.

How can I tell if research-grade retatrutide is genuine?

Ask for an HPLC chromatogram and, above all, a mass spectrometry result showing the intact molecule at about 4,731 g/mol, ideally from an independent laboratory, and make sure the certificate can be tied to the vial in front of you. A single purity percentage with no identity data is not enough for a molecule this size.

Is it legal to import retatrutide into Canada?

Importing an unauthorised drug for human use is not permitted, and research chemicals crossing the border can be held or refused by the Canada Border Services Agency. Sourcing research material from within Canada removes the border step entirely. Our article on importing research chemicals versus buying domestically sets out the differences.

ExoLabz supplies research materials for laboratory and in-vitro research by qualified professionals. Retatrutide is an investigational molecule with no Canadian market authorisation. Nothing on this page is medical advice, and nothing here describes, recommends or supports use in people or animals.